Search results for "Urologia"

showing 10 items of 1005 documents

Social distancing in chronic migraine during the covid-19 outbreak: Results from a multicenter observational study

2021

Background: The restrictions taken to control the rapid spread of COVID-19 resulted in a sudden, unprecedented change in people’s lifestyle, leading to negative consequences on general health. This study aimed to estimate the impact of such changes on migraine severity during 2020 March–May lockdown. Methods: Patients affected by migraine with or without aura, diagnosed by expert physicians, completed a detailed interview comprehensive of: assessment of migraine characteristics

AdultSleep Wake Disordersmedicine.medical_specialtyAuraMigraine DisordersPhysical DistancingMetabolic equivalentArticle03 medical and health sciences0302 clinical medicineChronic MigraineQuality of lifeInternal medicineSurveys and QuestionnairesEpidemiologymedicineHumansTX341-641030212 general & internal medicineExerciseLife StyleMigraineNutritionSleep disorderSleep disorderNutrition and DieteticsCOVID-19; Migraine; Nutrition; Physical activity; Quarantine; Sleep disorder; Adult; COVID-19; Communicable Disease Control; Exercise; Feeding Behavior; Headache; Humans; Italy; Life Style; Middle Aged; Migraine Disorders; Quality of Life; Quarantine; SARS-CoV-2; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Physical Distancingbusiness.industryNutrition. Foods and food supplyPhysical activitySARS-CoV-2HeadacheCOVID-19Feeding BehaviorMiddle Agedmedicine.diseaseMigraineItalyQuarantineCommunicable Disease ControlQuality of LifeObservational studySettore MED/26 - Neurologiasense organsbusinessSleep030217 neurology & neurosurgeryFood Science
researchProduct

Double Negative (CD19+IgG+IgD-CD27-) B Lymphocytes: A New Insight from Telomerase in Healthy Elderly, in Centenarian Offspring, and in Alzheimer’s Di…

2014

Background: We have previously reported the increase of IgD-CD27- (Double Negative, DN) B cell population in the aged. These memory B cells have short telomeres and poor abilities to proliferate in vitro. Here, we investigated whether the low ability of DN B cells to proliferate depends on the expression levels of the CD307d and CD22 inhibitory receptors or whether DN B cells can proliferate and reactivate telomerase by the engagement of both innate and adaptive immune receptors. Methods: Phenotypic analyses were made by using flow cytometry. Quantitative analysis of telomerase activity was made by using a TRAP and a photometric enzyme immunoassay in young, healthy elderly, centenarian offs…

AdultTelomeraseAgingImmunologyPopulationNaive B cellB-Lymphocyte SubsetsReceptors Antigen B-CellCentenarian offspringLymphocyte ActivationSeverity of Illness IndexCD19ImmunophenotypingYoung AdultAlzheimer DiseasemedicineIgD-CD27- (Double Negative DN) B cell population in the aged DN B cell telomerase activity in young elderly CO and AD patientsImmunology and AllergySettore MED/05 - Patologia ClinicaHumanseducationTelomeraseB cellCellular SenescenceAgedInflammationSettore MED/04 - Patologia GeneraleAged 80 and overeducation.field_of_studyCD40biologyB lymphocyteAge FactorsTLR9ImmunosenescenceMiddle Agedmedicine.anatomical_structurePhenotypeImmunologyAntigens Surfacebiology.proteinAlzheimerAging; Telomerase; B lymphocytes; Alzheimer; Centenarian offspring; InflammationSettore MED/26 - NeurologiaImmunologic Memory
researchProduct

Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations

2001

The prevalence and pattern of cognitive impairment in systemic lupus erythematosus (SLE) patients with (NPSLE) and without (nSLE) overt neuropsychiatric manifestations were investigated. Fifty-two nSLE patients, 23 NPSLE patients and 27 healthy controls were evaluated with a battery of standardized neuropsychological and psychological tests. Disease duration, disease activity index, and current corticosteroid therapy were collected. Cognitive impairment was identified in 14 (26.9%) and in 12 (52.2%) of subjects with nSLE and NPSLE, respectively. Both SLE groups showed a significant impairment compared with controls on tasks assessing verbal and non-verbal long-term memory, and visuoconstruc…

Adultmedicine.medical_specialtyAnxietyNeuropsychological TestsMental ProcessesAdrenal Cortex HormonesMemoryInternal medicinemedicineHumansLupus Erythematosus SystemicSpeechSystemic lupus erythematosus Neuropsychiatric SLE Cognitive impairment Neuropsychology DepressionAttentionPsychological testingEffects of sleep deprivation on cognitive performanceDepression (differential diagnoses)Psychiatric Status Rating ScalesLupus erythematosusDepressionCognitive disorderNeuropsychologymedicine.diseaseConnective tissue diseaseMemory Short-TermNeurologyMental RecallPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Cognition DisordersPsychologyPsychomotor PerformancePsychopathologyJournal of the Neurological Sciences
researchProduct

Paradoxical embolism through a patent foramen ovale from central venous catheter thrombosis: A potential cause of stroke

2020

Paradoxical embolism refers to a potential condition in which an embolus arising from a venous source crosses into the systemic circulation through a right-to-left cardiac shunt causing an arterial embolism. A 39-year-old woman carrier of a central venous catheter (CVC) without evident risk factors for stroke, developed an acute right homonymous hemianopia during hemodialysis. On neuroimaging, an infarct in the territory of the left posterior cerebral artery was demonstrated. Transesophageal echocardiography revealed a patent foramen ovale (PFO) and a large fluctuating thrombus in the right atrium on the tip of the CVC, thus allowing a diagnosis of ischemic stroke from paradoxical embolism.…

Adultmedicine.medical_specialtyArterial embolismCardioembolismmedicine.medical_treatmentEmbolismForamen Ovale Patent03 medical and health sciences0302 clinical medicineParadoxical embolismEmbolusUpper Extremity Deep Vein ThrombosisInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineThrombusStrokebusiness.industryCardiac shuntmedicine.diseasePatent foramen ovaleStrokeNeurologyPatent foramen ovaleCardiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCentral venous catheterEchocardiography Transesophageal030217 neurology & neurosurgeryCentral venous catheterEmbolism ParadoxicalJournal of the Neurological Sciences
researchProduct

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Myasthenia gravis associated with Charcot-Marie-Tooth neuropathy: report of a case

1992

We report the case of a 24 year old woman who developed myasthenia gravis in the course of a mild form of Charcot-Marie-Tooth neuropathy. We describe the clinical manifestations together with the neurophysiological, pathological, serological findings and response to therapy and discuss the unusual association in the light of the relevant literature. © 1992 Masson Italia Periodici S.r.l.

Adultmedicine.medical_specialtyNeurologyResponse to therapySural nerve biopsySural NerveCharcot-Marie-Tooth DiseaseMyasthenia GravismedicineHumansReceptors CholinergicMild formPathologicalsural nerve biopsyNeuroscience (all)business.industryGeneral Neuroscienceanti-acetylcholine receptor antibodiemedicine.diseaseDermatologymyasthenia graviMyasthenia gravisSurgeryFemaleSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessCharcot-Marie-Tooth neuropathy
researchProduct

Activation-Induced Rigidity in Neurologically and Cognitively Healthy Individuals Aged 18-90 Years: A Cross-Sectional Study.

2021

Background: Rigidity is a key clinical feature of Parkinson’s disease (PD), but in a very early phase of the disease it may be absent and can be enhanced through active movements of the arm contralateral to the one being tested. Objective: To evaluate in a large cohort of neurologically and cognitively healthy (NCH) subjects aged 18–90 years if activation-induced rigidity (AR) is present in all age classes, and if there are biological differences between subjects showing AR (AR+) and not showing AR (AR-). Methods: 2,228 NCH subjects categorized as young adult (18–44 years), adult (45–64 years), elderly (65–74 years), and old/oldest-old (75–90 years) were included in the analysis, and underw…

Adultmedicine.medical_specialtyParkinson's diseaseAdolescentCross-sectional studyAudiologylacunesProdromal phaseYoung AdultCellular and Molecular NeuroscienceLateral ventriclesCognitionAtrophyHumansMedicinehealthy aging subjectscaudate atrophyYoung adultAgedglobal cerebral atrophyAged 80 and overActivation-induced rigiditybusiness.industryBrainParkinson DiseaseMiddle Agedwhite matter hyperintensitiesmedicine.diseaseMagnetic Resonance ImagingHyperintensityCross-Sectional StudiesHealthy individualsSettore MED/26 - NeurologiaNeurology (clinical)Atrophybusiness
researchProduct

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct